Last reviewed · How we verify

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin

American University of Beirut Medical Center · FDA-approved active Small molecule

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin is a Proton pump inhibitor + antibiotic combination therapy Small molecule drug developed by American University of Beirut Medical Center. It is currently FDA-approved for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis. Also known as: Rabeprazole: Pariet, Metronidazole: Flagyl, Clarithromycin: Klacid, Amoxicillin: Amoxil.

This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid and simultaneously attacking the bacteria with three antibiotics.

This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid and simultaneously attacking the bacteria with three antibiotics. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.

At a glance

Generic nameRabeprazole, metronidazole, Clarithromycin, Amoxicillin
Also known asRabeprazole: Pariet, Metronidazole: Flagyl, Clarithromycin: Klacid, Amoxicillin: Amoxil
SponsorAmerican University of Beirut Medical Center
Drug classProton pump inhibitor + antibiotic combination therapy
TargetH+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
ModalitySmall molecule
Therapeutic areaGastroenterology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Rabeprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment where the three antibiotics (metronidazole, clarithromycin, and amoxicillin) can effectively penetrate and kill H. pylori. Metronidazole and clarithromycin are bactericidal agents that disrupt bacterial protein synthesis and DNA, while amoxicillin inhibits bacterial cell wall synthesis. The combination approach reduces antibiotic resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rabeprazole, metronidazole, Clarithromycin, Amoxicillin

What is Rabeprazole, metronidazole, Clarithromycin, Amoxicillin?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin is a Proton pump inhibitor + antibiotic combination therapy drug developed by American University of Beirut Medical Center, indicated for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.

How does Rabeprazole, metronidazole, Clarithromycin, Amoxicillin work?

This is a quadruple therapy combination that eradicates Helicobacter pylori by suppressing gastric acid and simultaneously attacking the bacteria with three antibiotics.

What is Rabeprazole, metronidazole, Clarithromycin, Amoxicillin used for?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin is indicated for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.

Who makes Rabeprazole, metronidazole, Clarithromycin, Amoxicillin?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin is developed and marketed by American University of Beirut Medical Center (see full American University of Beirut Medical Center pipeline at /company/american-university-of-beirut-medical-center).

Is Rabeprazole, metronidazole, Clarithromycin, Amoxicillin also known as anything else?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin is also known as Rabeprazole: Pariet, Metronidazole: Flagyl, Clarithromycin: Klacid, Amoxicillin: Amoxil.

What drug class is Rabeprazole, metronidazole, Clarithromycin, Amoxicillin in?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin belongs to the Proton pump inhibitor + antibiotic combination therapy class. See all Proton pump inhibitor + antibiotic combination therapy drugs at /class/proton-pump-inhibitor-antibiotic-combination-therapy.

What development phase is Rabeprazole, metronidazole, Clarithromycin, Amoxicillin in?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin is FDA-approved (marketed).

What are the side effects of Rabeprazole, metronidazole, Clarithromycin, Amoxicillin?

Common side effects of Rabeprazole, metronidazole, Clarithromycin, Amoxicillin include Diarrhea, Nausea, Abdominal pain, Headache, Metallic taste (metronidazole), Vomiting.

What does Rabeprazole, metronidazole, Clarithromycin, Amoxicillin target?

Rabeprazole, metronidazole, Clarithromycin, Amoxicillin targets H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin) and is a Proton pump inhibitor + antibiotic combination therapy.

Related